By Michele Maatouk
Date: Monday 02 Feb 2026
(Sharecast News) - GSK is planning to cut as many as 350 jobs in research & development in the UK and US, it was announced on Monday.
| Total Voting Rights | 02-Feb-2026 | 15:00 | RNS |
| European Commission approves Arexvy for adults 18+ | 26-Jan-2026 | 07:00 | RNS |
| GSK to acquire RAPT Therapeutics | 20-Jan-2026 | 07:05 | RNS |
| Agreement on changes to ViiV minority shareholding | 20-Jan-2026 | 07:00 | RNS |
| Director/PDMR Shareholding | 16-Jan-2026 | 15:30 | RNS |
| GSK looking at future cost savings and manufactu... | 02-Feb-2026 | Times |
| GSK to buy US food allergy specialist for $2.2bn | 20-Jan-2026 | Times |
| GlaxoSmithKline scraps sale of old drugs | 05-Dec-2014 | Telegraph |
| Glaxo sharpens axe to save £1bn as insurers and ... | 01-Dec-2014 | The Independent |
| GSK to cut hundreds of US jobs | 01-Dec-2014 | Telegraph |
| Questor :GlaxoSmithKline | 16-Apr-2014 | Telegraph |
| Questor:GlaxoSmithKline | 06-Oct-2011 | Telegraph |
| Questor:GlaxoSmithKline | 11-Aug-2011 | Telegraph |
| Questor tip: GlaxoSmithKline | 28-Jul-2011 | Telegraph |
| Investment Column: GlaxoSmithKline | 27-Jul-2011 | The Independent |
| Currency | UK Pounds |
| Share Price | 1,925.00p |
| Change Today | 48.50p |
| % Change | 2.58 % |
| 52 Week High | 1,927.50 |
| 52 Week Low | 1,264.00 |
| Volume | 12,846,713 |
| Shares Issued | 4,076.08m |
| Market Cap | £78,465m |
| Beta | 1.03 |
| RiskGrade | 129 |
| Value | ![]() |
|---|
| Price Trend |
|
|---|
| Income | ![]() |
|---|
| Growth | ![]() |
|---|
| Strong Buy | 4 |
| Buy | 3 |
| Neutral | 13 |
| Sell | 3 |
| Strong Sell | 0 |
| Total | 23 |

| Latest | Previous | |
|---|---|---|
| Q3 | Q2 | |
| Ex-Div | 13-Nov-25 | 14-Aug-25 |
| Paid | 08-Jan-26 | 09-Oct-25 |
| Amount | 16.00p | 16.00p |
| Time | Volume / Share Price |
| 14:44 | 1 @ 1,921.00p |
| 14:41 | 0 @ 1,917.50p |
| 14:40 | 1 @ 1,915.00p |
| 14:40 | 1 @ 1,915.00p |
| 14:40 | 1 @ 1,915.00p |
You are here: research